1 / 10

Oncology/Cancer Drugs Market by Therapeutic Modalities and Cancer Types

The global oncology drugs market is experiencing a shift in therapeutic modalities i.e. from traditional cytotoxic agents to newly develop targeted and immunotherapeutic modalities. Tumor cell specificity, an attribute of aforementioned modality has reduced drug remission rates and has rendered an enhanced rate of survival in cancer patients thus, complementing the market growth. However, chemotherapeutic modalities would continue to be the leading therapeutic modality segment owing to its higher adoption rate and economic pricing. Going forward, the demand for the chemotherapy modality might confront a negative influence due to marginal efficacy and chronic side effects such as anemia.

swati_tamhankar
Download Presentation

Oncology/Cancer Drugs Market by Therapeutic Modalities and Cancer Types

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Opportunity Analysis and Industry Forecast, 2016-2023 Oncology/Cancer Drugs Market by Therapeutic Modalities and Cancer Types Global Opportunity Analysis and Industry Forecast, 2016-2023

  2. ONCOLOGY/CANCER DRUGS MARKET Global Oncology Drugs Market is registering a CAGR of 7.1% from 2014 to 2020 and is expected to reach $111.9 billion by 2020, according to new research published by Allied Market Research. Increase in adoption of combination therapies instead of traditional cytotoxic therapies is a major factor that contributes to the market growth. The combinational therapies which include targeted therapy and immunotherapy (Biologic therapy), is expected to witness ~10% surge in its market share collectively by 2020. The global oncology drugs market is experiencing a shift in therapeutic modalities i.e. from traditional cytotoxic agents to newly develop targeted and immunotherapeutic modalities. Tumor cell specificity, an attribute of aforementioned modality, has reduced drug remission rates and has rendered an enhanced rate of survival in cancer patients thus, complementing the market growth. However, chemotherapeutic modalities would continue to be the leading therapeutic modality segment owing to its higher adoption rate and economic pricing. Going forward, the demand for the chemotherapy modality might confront a negative influence due to marginal efficacy and chronic side effects such as anemia.

  3. ONCOLOGY/CANCER DRUGS MARKET Global cancer drugs market by cancer type is segmented into Blood cancer, Breast cancer, gastrointestinal tract cancer, Prostate cancer, Lung Cancer, Skin Cancer and other cancer. Amongst these different cancer types, blood cancer was the largest revenue generating segment in 2015. The growth of blood cancer segment is majorly due to the high cost of the drugs used to treat blood cancer. The prevalence of blood cancer is less in developed nations, however, the diagnosis rate is more than 90% and almost every person diagnosed with blood cancer seeks complete treatment for the cure of blood cancer. Due to the high disposable incomes of consumers in developed nations, expensive drug therapy of blood cancer is affordable in these regions. Majority of the recently evolved biologics (drugs based on monoclonal antibodies) showed a significant cure for blood cancer; therefore, usage rate of these drug is high, despite of their high cost.  Download Free Sample Report: https://www.alliedmarketresearch.com/request-sample/121

  4. ONCOLOGY/CANCER DRUGS MARKET Blood Cancer Blood Cancer Skin Cancer

  5. ONCOLOGY/CANCER DRUGS MARKET • Key Findings of Oncology Drugs Market: • Immunotherapy/biological drugs segment expected to grow at a double digit CAGR during the forecast period and would grow at the fastest rate • Blood cancer is the major revenue generating segment in the global oncology drug application market however, lung cancer segment is expected to grow fastest among all • Currently, North America garners a major share in the oncology drugs market, in terms of market size • Asia Pacific oncology drug market is dominated by China and Japan, together contributing to ~60% of the regional market revenue in 2017

  6. ONCOLOGY/CANCER DRUGS MARKET

  7. ONCOLOGY/CANCER DRUGS MARKET

  8. ONCOLOGY/CANCER DRUGS MARKET A majority of the oncology drug manufacturers have adopted collaboration and acquisition as key developmental strategies to achieve a competitive edge. Moreover, companies are also forming strategic alliances to accelerate the process of clinical trials. These strategies have proved to be effective in helping key market players retain their leading positions in the global oncology drugs market. Key companies profiled in the report are Roche diagnostics, Novartis AG, Celgene Corporation, AstraZeneca, Johnson & Johnson, Merck & Co., Eli Lilly & Co., Amgen Inc., Pfizer and GlaxoSmithKline. Do Purchase Report: https://www.alliedmarketresearch.com/purchase-enquiry/121

  9. ONCOLOGY/CANCER DRUGS MARKET Contact:Shriram Dighe5933 NE Win Sivers Drive#205, Portland, OR 97220United StatesToll Free: +1-800-792-5285UK: +44-845-528-1300Hong Kong: +852-301-84916India (Pune): +91-20-66346060Fax: +1⟨855⟩550-5975help@alliedmarketresearch.com Web: https://www.alliedmarketresearch.com

  10. ONCOLOGY/CANCER DRUGS MARKET Thank You! For More Details Visit us at https://www.alliedmarketresearch.com Follow Us On

More Related